Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Lymphoma, Follicular

In brief

The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Follicular Lymphoma (FL).

Key facts

Study ID
NCT00092274
Run by
GlaxoSmithKline
People needed
0
Starts
2004-09-01
Expected to finish
2005-01-01
Last updated by the study team
2015-04-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.